News Channels

10 Sep 2018 Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
10 Sep 2018 Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
10 Sep 2018 Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis
10 Sep 2018 Innovent's Anti-CD47 Antibody IBI188 Receives IND Approval in China
10 Sep 2018 Xbrane Biopharma announces product portfolio update with a new full strategic focus on biosimilars
10 Sep 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
10 Sep 2018 Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites
10 Sep 2018 Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
10 Sep 2018 CCAB and Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates
10 Sep 2018 European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
10 Sep 2018 GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
08 Sep 2018 European Commission Expands Labelling for Janssen’s INVOKANA® and VOKANAMET® to Include Positive Data on Cardiovascular Outcomes
08 Sep 2018 Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
08 Sep 2018 CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit
08 Sep 2018 Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness
08 Sep 2018 CYTOO enters into Research and Option Agreement with Pfizer to develop a target discovery platform for Duchenne Muscular Dystrophy
08 Sep 2018 Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata
07 Sep 2018 Zealand sells royalty streams and milestones for USD 205 million to Royalty Pharma
07 Sep 2018 Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
07 Sep 2018 ITF Pharma Announces FDA Approval Of TIGLUTIK™ (Riluzole) Oral Suspension For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up